Response Rates
n (%)
Lenvatinib (n = 261)
Placebo (n = 131)
ORR
169 (65%)
2 (2%)
95% CI
59.0–70.5
0.0–3.6
P
-value
<0.0001
Complete response
4 (2%)
0
Partial response
165 (63%)
2 (2%)
Stable disease ≥ 23 weeks
40 (15%)
39 (30%)
Progressive disease
18 (7%)
52 (40%)
Median time to objective
response, months (95% CI)
a
2.0 (1.9–3.5)
–
Duration of response, months,
median (95% CI)
NR (16.8–NR)
–
Schlumberger M, et al.
N Engl J Med
2015
